Caffeine and Progression of Parkinson Disease.
Simon, DK, CJ Swearingen, RA Hauser, JM Trugman, MJ Aminoff, C Singer, D Truong, and BC Tilley. 2008. “Caffeine and Progression of Parkinson Disease.”. Clin Neuropharmacol.
Search
Search results
812 results found
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Hauser, RA, LM Shulman, JM Trugman, JW Roberts, A Mori, R Ballerini, and NM Sussman. 2008. “Study of Istradefylline in Patients With Parkinson’s Disease on Levodopa With Motor Fluctuations.”. Mov Disord.
Medical treatment of motor and nonmotor features of Parkinson’s disease.
Zesiewicz, TA, and RA Hauser. 2007. “Medical Treatment of Motor and Nonmotor Features of Parkinson’s Disease.”. Continuum.
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson’s disease.
Hauser, RA, L Salin, N Juhel, and VL Konyago. 2007. “Randomized Trial of the Triple Monoamine Reuptake Inhibitor NS 2330 (tesofensine) in Early Parkinson’s Disease.”. Movement Disorders.
Initial management of Parkinson’s disease in a Florida community. J Applied Research 2004;4:95-98.
Zesiewicz, TA, SN Carter, KL Sullivan, JS Staffetti, PB Dunne, and RA Hauser. 2004. “Initial Management of Parkinson’s Disease in a Florida Community. J Applied Research 2004;4:95-98.”. J Applied Research.
Substantial improvement in a Meige's syndrome patient with levetiracetam treatment. Movement Disorders 2004;19:1518-1521.
Zesiewicz, TA, ED Louis, KL Sullivan, M Menkin, PB Dunne, and RA Hauser. 2004. “Substantial Improvement in a Meige’s Syndrome Patient With Levetiracetam Treatment. Movement Disorders 2004;19:1518-1521.”. Movement Disorders.
Essential tremor. Epidemiology, diagnosis, and treatment. Neurologist 2004;10:250-258.
Sullivan, KL, RA Hauser, and TA Zesiewicz. 2004. “Essential Tremor. Epidemiology, Diagnosis, and Treatment. Neurologist 2004;10:250-258.”. Neurologist.
Double-blinded, placebo-controlled study of entacapone in levodopa-treated patients with Parkinson disease. Archives of neurology, 61(10), 1563.
Olanow, CW, K Kieburtz, M Stern, R Watts, JW Langston, M Guarnieri, RA Hauser, and J Hubble. 2004. “Double-Blinded, Placebo-Controlled Study of Entacapone in Levodopa-Treated Patients With Parkinson Disease. Archives of Neurology, 61(10), 1563.”. Archives of Neurology.
Autonomic nervous system dysfunction in Parkinson’s disease. Curr Treat Options Neurol 2003; 5:149-160.
Zesiewicz, TA, MJ Baker, M Wahba, and RA Hauser. 2003. “Autonomic Nervous System Dysfunction in Parkinson’s Disease. Curr Treat Options Neurol 2003; 5:149-160.”. Curr Treat Options Neurol.
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson’s disease.
Kase, H, S Aoyama, M Ichimura, K Ikeda, A Ishii, T Kanda, K Koga, and . 2003. “Progress in Pursuit of Therapeutic A2A Antagonists: the Adenosine A2A Receptor Selective Antagonist KW6002: Research and Development Toward a Novel Nondopaminergic Therapy for Parkinson’s Disease.”. Neurology.